Abstracts

CHARACTERISATION OF SARS-CoV-2–INFECTED CHILDREN DEVELOPING NEUTRALISING ANTIBODIES

Further knowledge on adaptive immunity to SARS-CoV-2 (CoV-2) in children is needed in order to define possible immunization strategies and reconsider pandemic control measures. We analyzed anti-CoV-2 antibodies (Ab) and their neutralizing activity (PRNT), alongside antigen (Ag) specific cellular response, in relation to virus load in nasopharyngeal swabs. We analysed 42 CoV-2 patients at 7…

DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS

ODYSSEY is an international multi-centre randomised non-inferiority trial evaluating dolutegravir (DTG) + 2NRTIs versus standard-of-care (SOC) in children starting first- or second-line ART. The primary outcome is a Kaplan-Meier estimated proportion of treatment failure defined as confirmed viral load (VL) ?400c/mL after week 36, lack of virological response by 24 weeks with ART switch, death…

ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010

Insufficient and excess weight gain during pregnancy have been associated with adverse pregnancy outcomes. We evaluated the association between antepartum weight gain and adverse pregnancy outcomes in secondary analyses of IMPAACT 2010 data. Women with HIV-1 in 9 countries were randomized 1:1:1 at 14-28 weeks gestational age (GA) to start dolutegravir (DTG)+emtricitabine(FTC)/tenofovir alafenamide fumarate (TAF)…

SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL

We previously reported safety and virologic efficacy of dolutegravir (DTG)+emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) vs DTG+FTC/tenofovir disoproxil fumarate (TDF) vs efavirenz (EFV)/FTC/TDF through delivery. We now present results from enrollment through week 50 postpartum (PP). Pregnant women with HIV-1 in 9 countries were randomized 1:1:1 to start open-label DTG+FTC/TAF, DTG+FTC/TDF, or EFV/FTC/TDF at 14-28 weeks…

ADVERSE PREGNANCY OUTCOMES AMONG HIV-INFECTED WOMEN EXPOSED TO ISONIAZID IN BRIEF-TB

Isoniazid (INH) preventive therapy (IPT), a key strategy for reducing tuberculosis (TB) and death among persons with HIV (PWH), was associated with increased composite adverse pregnancy outcomes in IMPAACT P1078 trial. The BRIEF-TB trial demonstrated non-inferiority of one-month of isoniazid and rifapentine versus nine months of IPT. We assessed adverse pregnancy outcomes among women exposed…

A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION

HTI is a novel HIV vaccine immunogen designed at redirecting cellular immune responses to HIV targets associated with viral control. The AELIX-002 trial (NCT03204617) was a randomized, single-center, placebo-controlled trial to evaluate the safety, immunogenicity and antiviral effect of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines after discontinuation of ART in early-treated people living…